Approved for VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.. Atrasentan is an endothelin A (ETA) receptor antagonist. Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA FAERS, and CMS NADAC pricing.
Loading full data from Know Your Drugs Institute…